Adma Biologics reported $203.84M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Adma Biologics USD 203.84M 567K Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 233.31M 4.23M Sep/2024
Omeros USD 442.16M 199K Sep/2023
Takeda JPY 4.58T 364.32B Sep/2026